327 related articles for article (PubMed ID: 35717838)
21. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
Zhang K; Ye K; Tang H; Qi Z; Wang T; Mao J; Zhang X; Jiang S
J Med Chem; 2023 Apr; 66(7):4378-4416. PubMed ID: 36951608
[TBL] [Abstract][Full Text] [Related]
22. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
Chapman S; Kwa M; Gold LS; Lim HW
J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
[TBL] [Abstract][Full Text] [Related]
23. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
24. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
25. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
Zak M; Dengler HS; Rajapaksa NS
Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
[TBL] [Abstract][Full Text] [Related]
26. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
27. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
Shih PY; Li CJ; Yong SB
Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
[TBL] [Abstract][Full Text] [Related]
28. Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors.
Garrido-Trigo A; Salas A
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S713-S724. PubMed ID: 32083640
[TBL] [Abstract][Full Text] [Related]
29. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
[TBL] [Abstract][Full Text] [Related]
30. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
[TBL] [Abstract][Full Text] [Related]
31. JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
Jamilloux Y; El Jammal T; Vuitton L; Gerfaud-Valentin M; Kerever S; Sève P
Autoimmun Rev; 2019 Nov; 18(11):102390. PubMed ID: 31520803
[TBL] [Abstract][Full Text] [Related]
32. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
[TBL] [Abstract][Full Text] [Related]
33. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
Muddebihal A; Khurana A; Sardana K
Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
[TBL] [Abstract][Full Text] [Related]
34. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
Sardana K; Muddebihal A; Khurana A
Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
[TBL] [Abstract][Full Text] [Related]
35. JAK-STAT pathway inhibitors in dermatology.
Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
[TBL] [Abstract][Full Text] [Related]
36. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
37. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
38. JAK-STAT signaling pathway in non-infectious uveitis.
Su Y; Tao T; Liu X; Su W
Biochem Pharmacol; 2022 Oct; 204():115236. PubMed ID: 36041544
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and clinical application of small-molecule inhibitors of Janus kinase.
Zhang JY; Sun JF; Nie P; Herdewijn P; Wang YT
Eur J Med Chem; 2023 Dec; 261():115848. PubMed ID: 37793326
[TBL] [Abstract][Full Text] [Related]
40. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
